Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

Bone and Joint Infection Clinical Trial

Official title:

Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03848104
• Other study ID #: 18-079
• Status: Completed
• Start date: January 1, 2018
• Est. completion date: April 1, 2018

Study information

• Verified date: February 2019
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 1, 2018
• Est. primary completion date: March 1, 2018
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• patients havind had a bon and joint infeciton treated with cefoxitin in combination in continuous parenteral administration

Exclusion Criteria:

Related Conditions & MeSH terms

• Antibiotic Reaction
• Arthritis, Infectious
• Bone and Joint Infection
• Communicable Diseases
• Infection

Intervention

Other:
• bone and joint infection treated with cefoxitin
the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Treatment Failure	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Secondary	Rate of use of this strategy	Descriptions of patients managed with this strategy	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption